AI therapy has been shown to result in increased IGF-1 levels and an increased incidence of arthralgia in women treated for breast cancer, while tamoxifen reduced IGF-1 levels and the overall incidence of musculoskeletal side effects when used as adjuvant therapy [6]. Here, IGF1 is linked to breast carcinoma.